What Stimuli Technology does

Stimuli Technology is a private French medical device company headquartered in Boulogne-Billancourt, founded in 2018 and led by CEO Delphine Agullo. It designs, manufactures and distributes the Tensi+ medical device, a CE-marked hardware system that delivers transcutaneous electrical nerve stimulation (TENS) to the posterior tibial nerve at the inner ankle to treat idiopathic and neurological overactive bladder. The device is prescribed by urologists, gynecologists, rehabilitation physicians and general practitioners, used 20 minutes daily for a minimum 12-week course, and is reimbursed by France's Assurance Maladie, with clinical efficacy claims supported by peer-reviewed studies in Progrès en Urologie (2022), Canadian Journal of Urology (2023), Focus/Elsevier (2024) and Archivos Españoles de Urología (2026).

The product line centers on the Tensi+ device and a companion iOS/Android mobile application for therapy adherence, supported by recurring consumables: CE-marked electrodes, conductive gel and a positioning strap, plus a non-regulated aloe vera gel. Distribution runs through four channels — healthcare providers, medical equipment stores, pharmacies and online partner distributors — all of which require a medical prescription. The company operates under ISO 13485:2016 quality management certification and MDSAP certification, holds CE marking under EU MDR for its regulated devices, and has begun signaling cross-border European expansion through a six-language website and an initial Spanish clinical publication, while France remains its primary market.

Revenue is generated from one-time hardware sales plus recurring consumable purchases, with the device's inclusion in French national reimbursement materially expanding the addressable patient pool. The company's competitive position rests on regulatory clearances, published clinical evidence, a French Urology Association expert endorsement, and embedded distribution through pharmacies and clinicians, though it remains a small, private, single-product, single-country operator with no disclosed funding history, headcount, or revenue figures.

Name

Stimuli Technology

Legal name

Stimuli Technology

Website

https://stimuli-technology.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Urology Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

Keywords

• Overactive bladder treatment
• Medical nerve stimulation
• Tibial neurostimulation device
• TENS therapy device
• Urology medical device

Headquarters

HQ city

Boulogne-billancourt

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: Sale of Tensi+ medical devices for overactive bladder treatment. The device is reimbursed by French health insurance (Assurance Maladie) under medical prescription, suggesting a model where patients obtain the device through healthcare providers with insurance coverage.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Stimuli Technology designs, manufactures, and distributes the Tensi+ medical device, a CE-marked transcutaneous electrical nerve stimulation (TENS) system that treats overactive bladder (idiopathic or neurological) by stimulating the posterior tibial nerve at the inner ankle. Patients use the device 20 minutes daily for a minimum of 12 weeks, with clinical efficacy validated after 3 months of treatment. The product is prescribed by healthcare professionals, sold through pharmacies, medical equipment stores, healthcare providers, and online distributors, and is reimbursed by French national health insurance (Assurance Maladie).

Differentiator

Problem solved

Functional benefit

Brands

• Tensi+: Medical device for transcutaneous tibial nerve stimulation treatment of overactive bladder (idiopathic or neurological origin). The Tensi+ system uses TENS (Transcutaneous Electrical Nerve Stimulation) technology targeting the posterior tibial nerve.

Products and services

• Tensi+ Medical Device A non-medication, non-invasive CE-marked medical device that uses transcutaneous electrical nerve stimulation (TENS) applied to the posterior tibial nerve at the inner ankle to treat idiopathic or neurological overactive bladder. Used 20 minutes daily for 12 weeks or more, with clinically proven efficacy after 3 months of treatment. Prescribed by urologists, gynecologists, rehabilitation doctors, and GPs, and reimbursed by Assurance Maladie.
• Tensi+ Mobile Application

Quantifiable outcome

• Clinically proven efficacy after 3 months of treatment (12 weeks)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Urologists and Bladder SpecialistscoreStrategic or Co-development PartnerTensi+ was developed in consultation with urologists and overactive bladder specialists, incorporating clinical expertise in the design and development of the medical device. Healthcare professionals provide ongoing patient referrals and prescription services.
• Healthcare Providers and Medical Equipment DistributorscoreChannel Partner/ Reseller/ DistributorDistribution partners including healthcare providers, medical equipment stores, and pharmacies distribute Tensi+ to patients with valid medical prescriptions. Online partner distributors also enable direct-to-consumer sales through e-commerce channels.
• Association Française d'Urologie (AFU)minorStrategic or Co-development PartnerExpert group from the French Urology Association reviewed and evaluated the Tensi+ medical device, providing professional endorsement and clinical validation.

Scale indicators2 records

Recent moves3 records

Expansion highlights5 records

Direct peers

• blueWind Medical: blueWind Medical develops an injectable, miniature tibial neuromodulation device for OAB. It is a direct competitor using posterior tibial nerve stimulation for overactive bladder.
• Laborie (Urgent PC): Laborie owns the Urgent PC percutaneous tibial nerve stimulation system for OAB. It is a direct competitor to Tensi+ on the same tibial nerve stimulation approach for the same patient population.
• Valencia Technologies (eCoin): Valencia Technologies markets eCoin, a coin-shaped implantable tibial nerve stimulator for overactive bladder. It is the most direct tibial-nerve-modulation peer to Tensi+, addressing the same OAB indication through posterior tibial nerve stimulation.
• InControl Medical (INNOVO): InControl Medical markets INNOVO, an external electrical muscle stimulation device for stress urinary incontinence and pelvic floor conditions. Comparable to Tensi+ as a non-invasive, home-use electrical stimulation therapy for lower urinary tract dysfunction.
• Atlantic Therapeutics (Innovotherapy): Atlantic Therapeutics developed Innovotherapy, an external electrical stimulation device for urinary incontinence. Directly comparable to Tensi+ as a non-invasive electrical stimulation therapy targeting the same patient use cases.

Broad incumbents

• Medtronic (InterStim): Medtronic's InterStim is the market-leading sacral neuromodulation system for OAB and fecal incontinence. It is the dominant incumbent in the broader OAB neuromodulation category in which Tensi+ competes.
• BTL Industries: BTL Industries manufactures a broad portfolio of rehabilitation, physical therapy, and aesthetic electrotherapy devices. Comparable to Tensi+ on the underlying electrotherapeutic device manufacturing capability and PT modality category, though not a direct OAB competitor.
• Axonics: Axonics markets sacral neuromodulation systems for OAB and fecal incontinence. A broader incumbent in the OAB neuromodulation space competing against Tensi+ on the same clinical indication via a different stimulation approach.

Emerging players

• Renovia: Renovia developed the leva digital pelvic floor rehabilitation system for urinary incontinence. An emerging player with partial overlap on the OAB/incontinence indication, combining a connected device with a digital therapeutic approach analogous to Tensi+'s mobile-app-enabled model.

Others

• Schwa-Medico: Schwa-Medico is a European TENS and electrotherapy device manufacturer supplying general pain management and rehabilitation use cases. Comparable as a European manufacturer of TENS-class devices in the same modality category, though not focused on OAB.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/stimuli-technology

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stimuli Technology